SNX17 mediates STAT3 activation to promote hepatocellular carcinoma progression via a retromer dependent mechanism

Yuqi Liu, Wei Tian, Chao Ge, Chongqin Zhang, Z.-x. Huang, Chengqi Zhang, Yue Yang, Hua TianInternational Journal of Biological Sciences 2025 · DOI

Abstract

Endocytosis has emerged as a key regulator of malignant behavior in cancer. Members of the sorting nexin (SNX) family have been found to be dysregulated in various cancers and play significant roles in regulating tumor metastasis. However, the role and mechanism of SNX17 in hepatocellular carcinoma (HCC) progression remain largely unknown. Here, we found that upregulation of SNX17 in HCC was associated with poor prognosis. Overexpression of SNX17 promoted HCC cell proliferation, migration, invasion, and metastasis, whereas silencing SNX17 expression resulted in opposite effects. Knockdown of SNX17 induced G1/S phase arrest and apoptosis. We discovered that SNX17 directly interacted with STAT3 and increased its phosphorylation in a retromer-dependent manner. SNX17-retromer complex acted as a platform for IL-6-induced STAT3 activation. Activated STAT3 then increased c-Myc expression and promoted mitochondrial oxidative phosphorylation (OXPHOS) and mitochondrial biogenesis. SNX17 overexpression-induced OXPHOS was reversed by c-Myc inhibitor. Knockdown of STAT3 expression or treatment with a STAT3 inhibitor significantly attenuated SNX17-enhanced proliferation and invasion. Taken together, our results indicate that SNX17 promotes HCC cell proliferation and metastasis through direct interaction with STAT3 in a retromer-dependent manner, thereby activating the STAT3/c-Myc signaling pathway and enhancing OXPHOS. These findings suggest that SNX17 is a potential therapeutic target for HCC.

Introduction

Hepatocellular carcinoma (HCC) is a major global health challenge, characterized by high malignancy and limited therapeutic options for advanced stages. While the hijacking of endocytic pathways is a known hallmark of cancer, the specific contributions of sorting nexins in HCC have remained poorly understood. This study identifies SNX17 (Sorting Nexin 17) as a critical oncogenic driver that facilitates a metabolic shift toward increased mitochondrial energy production, thereby promoting tumor growth and metastasis.

Methodology

To investigate the role of SNX17, researchers employed a multi-faceted approach:

  • Bioinformatics: Analysis of large-scale patient datasets from TCGA, GEO (GSE36376, GSE39791, GSE148335), and ICGC to correlate SNX17 expression with clinical outcomes.
  • Molecular Biology: Immunoprecipitation-Mass Spectrometry (IP-MS) to identify SNX17-interacting proteins, and functional assays (overexpression/knockdown) in HCC cell lines.
  • Metabolic Profiling: Real-time measurement of Oxygen Consumption Rate (OCR) using Seahorse XFe 96 analyzers to assess mitochondrial respiration.
  • In Vivo Validation: Orthotopic liver tumor models in mice to evaluate tumor growth and metastatic potential.
  • Clinical Validation: Immunohistochemistry (IHC) on a cohort of 90 HCC tissue samples from the Affiliated Hospital of Youjiang Medical College for Nationalities.

Results and Clinical Significance

Clinical Correlation and Prognosis

Data from multiple genomic repositories and clinical cohorts demonstrate that SNX17 is significantly overexpressed in HCC compared to normal liver tissue. This upregulation is strongly associated with advanced tumor stages, nodal metastasis, and significantly poorer overall and disease-free survival rates.

Figure 1: Comprehensive clinical and experimental analysis of SNX17 in HCC. (A-D) mRNA expression across datasets. (E) Western blot validation in patient tissues. (F-H) Correlation with clinical stage. (I) IHC staining of low vs. high expression. (J-L) Survival analysis. (M) Cox regression analysis identifying SNX17 as an independent prognostic factor.

The SNX17-STAT3-Retromer Axis

The study reveals that SNX17 acts as a molecular scaffold, directly interacting with STAT3 and the retromer complex (specifically VPS35 and VPS26A). This complex serves as a platform for IL-6-induced STAT3 activation. Once phosphorylated, STAT3 upregulates the c-Myc oncogene, which in turn enhances mitochondrial biogenesis and oxidative phosphorylation (OXPHOS). This metabolic reprogramming provides the energy necessary for the invasive and proliferative behaviors of HCC cells.

Functional Impact

Overexpression of SNX17 markedly increased HCC cell proliferation, migration, and invasion. Conversely, silencing SNX17 induced cell cycle arrest at the G1/S phase and triggered apoptosis. In mouse models, SNX17-overexpressing tumors exhibited a higher frequency of intrahepatic metastasis. Importantly, these effects were significantly reversed by STAT3 inhibition or c-Myc inhibitors, confirming the pathway's critical role.

Discussion and Future Directions

This study establishes SNX17 as a key link between protein trafficking and cancer metabolism. By acting as a scaffold for STAT3 activation, SNX17 drives the metabolic surge required for HCC progression.

While this work highlights the SNX17-STAT3 axis, the identification of over 400 other potential SNX17 interactors suggests additional roles in HCC that remain to be explored. Furthermore, the correlation between SNX17 and M2 macrophage infiltration points toward a potential influence on the tumor microenvironment. Future research should focus on developing targeted therapies to disrupt the SNX17-STAT3-Retromer interface, offering a new avenue for HCC treatment.

Summary updated

Abstract

Endocytosis has emerged as a key regulator of malignant behavior in cancer. Members of the sorting nexin (SNX) family have been found to be dysregulated in various cancers and play significant roles in regulating tumor metastasis. However, the role and mechanism of SNX17 in hepatocellular carcinoma (HCC) progression remain largely unknown. Here, we found that upregulation of SNX17 in HCC was associated with poor prognosis. Overexpression of SNX17 promoted HCC cell proliferation, migration, invasion, and metastasis, whereas silencing SNX17 expression resulted in opposite effects. Knockdown of SNX17 induced G1/S phase arrest and apoptosis. We discovered that SNX17 directly interacted with STAT3 and increased its phosphorylation in a retromer-dependent manner. SNX17-retromer complex acted as a platform for IL-6-induced STAT3 activation. Activated STAT3 then increased c-Myc expression and promoted mitochondrial oxidative phosphorylation (OXPHOS) and mitochondrial biogenesis. SNX17 overexpression-induced OXPHOS was reversed by c-Myc inhibitor. Knockdown of STAT3 expression or treatment with a STAT3 inhibitor significantly attenuated SNX17-enhanced proliferation and invasion. Taken together, our results indicate that SNX17 promotes HCC cell proliferation and metastasis through direct interaction with STAT3 in a retromer-dependent manner, thereby activating the STAT3/c-Myc signaling pathway and enhancing OXPHOS. These findings suggest that SNX17 is a potential therapeutic target for HCC.
BibTeX
@article{liu2025snx,
  author = {Yuqi Liu and Wei Tian and Chao Ge and Chongqin Zhang and Z.-X. Huang and Chengqi Zhang and Yue Yang and Hua Tian},
  title = {{SNX17 mediates STAT3 activation to promote hepatocellular carcinoma progression via a retromer dependent mechanism}},
  journal = {International Journal of Biological Sciences},
  year = {2025},
  doi = {10.7150/ijbs.110506},
}
Figure